Claudin 18 Antibody, Rabbit MAb from Sino Biological, Inc.

Yes, the Anti-Claudin-18 mAb is specifically designed for immunohistochemistry applications, allowing for the evaluation of Claudin-18.2 expression in various cancer tissues, including gastric, pancreatic, and esophageal cancers. This assessment is crucial for patient stratification and optimizing treatment strategies.

The Anti-Claudin-18 mAb has been noted for its excellent signal-to-noise ratio, even at lower concentrations, and is comparable to high-quality commercial antibodies. It has shown high specificity and sensitivity, making it a reliable choice for researchers.

Yes, this antibody recognizes both Claudin-18.1 and Claudin-18.2, which is beneficial for studies focusing on the therapeutic targeting of Claudin-18.2, as both isoforms may play roles in cancer biology.

Utilizing the Anti-Claudin-18 mAb for precise immunohistochemical assessment of Claudin-18.2 is vital for identifying patients who are most likely to benefit from targeted therapies. Clinical studies have indicated that patients with Claudin-18.2 positive tumors tend to have better treatment outcomes, underscoring the importance of accurate detection in personalizing treatment strategies.